Jeff Bridges is loving life after being ‘close to dying’ because of Covid and chemo
Jeff Bridges has a message now that he’s on the other side of Covid and his cancer is in remission: “Love is the deal.”
Posts Tagged ‘ COVID ’
Jeff Bridges has a message now that he’s on the other side of Covid and his cancer is in remission: “Love is the deal.”
A Belgian Olympian has been released from isolation in Beijing, following an emotional plea for help about her treatment ahead of the Winter Games.
Many tennis commentators say Novak Djokovic is all but unbeatable in Australia. He is, after all, the winner of a remarkable nine Australian Open Grand Slam titles. And, as the Australian government discovered this week, it hasn’t proven easy to defeat him in a court of law, either
Do you have a sore throat, a runny nose and muscle aches? It could be a common cold, a case of the flu — or Covid-19.
The US is ringing in the new year amid a Covid-19 surge experts warn is exploding at unprecedented speed and could alter daily life for many Americans during the first month of 2022.
Rock music icon Brian May has urged the public to get the Covid-19 vaccine, after telling fans on Instagram he’s been having a “truly horrible” time since testing positive for the virus last week.
Sens. Elizabeth Warren and Cory Booker tested positive for the coronavirus, according to tweets Sunday from their official accounts.
Johannesburg (CNN)South African President Cyril Ramaphosa is receiving treatment for mild Covid-19 symptoms after testing positive on Sunday, the office of the presidency said in a statement.
As more and more COVID-19 patients pour into hospitals around New York City, fourth-year Einstein medical students are volunteering for a program to help healthcare workers cope with the increasing demand for care.
Launched just one week ago, the program started with four students who were assigned to a special floor at Children’s Hospital at Montefiore (CHAM), where elective surgeries have been canceled to accommodate the influx of adult COVID-19 patients. (Four additional fourth-year medical students started working keen shoes with pediatricians earlier this week—two on the Moses campus and two at Jacobi Medical Center.)
Working as subinterns in tandem with hospital teams, the four CHAM volunteers are taking on 12-hour shifts, supporting pediatricians in the care of adult patients. Currently, it is the only program where Einstein medical students are working on the wards, and it is entirely voluntary.
“Everyone in the medical community is going above and beyond to help these patients,” said one of the fourth-years at CHAM, Corin Kinkhabwala. “This is where Einstein and Montefiore thought we would be most utilized and provide the best assistance. There are a lot of moving pieces. It’s very fluid, and you have to be adaptable.”
Todd Cassese, M.D., assistant dean for clinical sciences at Einstein, said each fourth-year “is caring for three to four patients and reporting back to the resident and attending physicians. The students are also providing advice on other patients on their teams.”
CHAM’s pediatric hospital medicine division chief, Patricia Hametz, M.D., said the fourth-year volunteers “have been truly amazing. They have stepped right up and become fully integrated members of the team. We are extremely grateful for the help as we all learn together how to care for this patient population.”
A Call for Action
When the COVID-19 pandemic started escalating in the Bronx in early March, medical school graduation was less than three months away. By mid-March, Einstein sent an email to gauge interest among the fourth-years in helping care for patients with COVID-19. “The fact that they reached out made me realize how dire the situation was,” Mr. Kinkhabwala said. Dozens of fourth-years volunteered.
Using a random name nike outlet generator, Dr. Cassese, working with the office of student affairs, selected four students: Mr. Kinkhabwala, Keara English, Michael Longo, and Marika Osterbur-Badhey. “We decided to start small and then grow the effort,” Dr. Cassese explained.
Josh Nosanchuk, M.D., Einstein’s senior associate dean for medical education, said the four piloting the program are “displaying their passion and compassion for our community. I couldn’t be more impressed or proud as they beautifully represent the heart and soul of Einstein”
Some of the adult patients who present with COVID-19 symptoms in the emergency departments at Montefiore are being sent to the converted floor at CHAM, where patients are sick enough to be hospitalized but do not require a ventilator. Patients who grow more ill are transferred to a different care team or the intensive-care unit.
Fourth-year volunteer Keara English says things were changing constantly due to need to accommodate the rapid influx of new patients, “but all the physicians—the attendings, residents, and interns—adapted quickly. I am proud to be able to work with them. Everyone is really trying to do their best to help our patients.”
To minimize the number of times healthcare staff go in and out of hospital rooms, a lot of the care is done by checking patient monitors connected to screens in the hallway and communicating with patients by telephone. “We are being paired with pediatric interns,” Ms. English said, “and basically just take the load off of them by checking the patients’ charts, making sure the lab reports come back, writing progress notes and discharge summaries, and communicating with the nursing staff, respiratory therapists, social work staff, and the family.”
Rhonda Acholonu, M.D., Montefiore’s vice chair for education in the department in pediatrics, said she worked alongside some of the fourth-years on overnight shifts at CHAM. “They were incredibly engaged and helpful. They spent time talking to the patients via the phone and gathering outstanding histories. It just goes to show you that the spirit to help is deeply engrained in the Einstein student.”
A Connection to Their Team
The CHAM COVID-19 schedule involves working from 6 a.m. to 6 p.m. for three days, 6 p.m. to 6 a.m. the following three nights, and then skechers outlet three days off. “In times like these having continuity of teams is critical and can save lives,” Dr. Cassese said. “But we wanted the students to choose their schedules. They discussed it on their own and they decided to stick with their teams, and I think it was a great choice, but it was theirs.”
Mr. Kinkhabwala, who will start a residency in otolaryngology-head and neck surgery at the Medical University of South Carolina later in June, said, “Some patients are sicker than others. It’s tiring, but I love it. This is what I signed up for. The patients are great. They are so resilient. It helps me get up in the morning.”
Ms. English, who will begin her internship this summer at Memorial Sloan Kettering Cancer Center before starting her radiation oncology residency at Johns Hopkins in Baltimore next year, said she was motivated to volunteer at CHAM because of what she heard about the need for help from close friends who are interns in emergency medicine and internal medicine in New York City. “I knew that if there was anything I could do, I wanted to try and relieve that burden.”
She also felt a special kinship to the Bronx. “I love our community here,” Ms. English said. “There are a lot of patients here that, on a good day—with no COVID-19—struggle with their health. They deserve our best efforts.”
The oral drug, called Paxlovid, reduces the risk of hospitalization or death by almost 90% in early tests, according to Pfizer.
Pfizer has asked for emergency use authorization for its COVID-19 antiviral pill could be up consideration.
A day after Merck and Ridgeback Biotherapeutics received approval in the UK for their COVID-19 antiviral pill, Pfizer said Friday it has an antiviral drug that can cut the risk of hospitalization or death from COVID by 89%, according to data from clinical trials.
Called Paxlovid, Pfizer’s pill would be taken orally to skechers outlet fight the severe symptoms. Currently, the only antiviral medication authorized in the US requires a health care professional to administer the medication intravenously, through a needle, over five to 10 days. An easy-to-take pill could become part of a growing toolkit that doctors could use to fight COVID, which already includes the three COVID vaccines authorized for use in the US.
In September, data from Johns Hopkins University showed that around 1 in 500 Americans have died from the coronavirus. While the available COVID-19 vaccines are highly effective, millions of Americans have not been vaccinated. According to a September report from the Centers for Disease Control and Prevention, unvaccinated people are over 10 times more likely to get hospitalized and die from the disease than fully vaccinated people.
Here’s what we know about Pfizer’s antiviral pill. We’ll update this story as more details emerge. For more on COVID-19, here’s the latest on vaccine mandates, keeping your vaccine card hanovembndy and this year’s flu season.
What is Pfizer’s COVID-19 antiviral drug?
In the US, the three approved COVID vaccines from Moderna, Pfizer and Johnson & Johnson can protect you from infection. But for those already infected, antiviral drugs could reduce the chance of serious illness and reduce the risk of hospitalization and death.
If approved, Pfizer’s drug won’t replace the need for vaccines. Health officials see the vaccines and antiviral drugs working in tandem to nike outlet tame the pandemic: Vaccines can prevent infection and lessen the severity of illness if you get infected. Antiviral drugs can lessen the effects of the illness, including for those unvaccinated.
In clinical trials, Paxlovid reduced the risk of hospitalization or death by 89% when taken three days of symptoms for those who are at a higher risk of serious infection, Pfizer said.
The pharmaceutical giant said it intends to request emergency use authorization from the Food and Drug Administration “as soon as possible.” During its clinical trials, Pfizer said, reported side effects between those taking the antiviral drug and those taking the placebo were about the same.
How does it compare with molnupiravir, Merck’s COVID pill?
Merck applied for an emergency use authorization of its antiviral pill with the FDA in mid-October.
If given the go-ahead, the Merck antiviral drug molnupiravir would be the first approved in the US to be taken orally at home. Merck has said its pill can reduce the risk of hospitalization and death by 50% if taken within five days of the onset of symptoms for people who have tested positive and are at higher risk of serious illness.
An FDA advisory committee plans to meet at the end of November to consider Merck’s emergency use application for molnupiravir.
When could Pfizer antiviral pill be available in the US?
The New York Times reported that Pfizer’s pill could be available in the next few months, if approved by the FDA.
What would be Pfizer treatment course for its antiviral pill?
During Pfizer’s tests on the drug, patients took the pill orally every 12 hours for five days.
Will Pfizer’s drug be free?
Pfizer expects to produce enough pills for more than 180,000 people by the end of 2021 and for more than 21 million people by the middle of 2022, The New York Times reported. The US government is negotiating with Pfizer to buy enough pills for 1.7 million courses of treatment.
Pfizer hasn’t said whether that deal keen shoes means that the pill will be free to patients in the US. A Pfizer spokesperson told CNET: “Pfizer’s goal is to deliver safe and effective oral anti-viral therapeutic(s) as soon as possible and at an affordable price, subject to regulatory authorization.”
Separately, the US government is purchasing 1.7 million courses of Merck’s antiviral drug to provide if and when it is approved by the FDA.
For more on COVID-19, here’s the latest on COVID-19 vaccines for kids, what to know about mixing and matching vaccines and what is happening with booster shots.
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.
M | T | W | T | F | S | S |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||
5 | 6 | 7 | 8 | 9 | 10 | 11 |
12 | 13 | 14 | 15 | 16 | 17 | 18 |
19 | 20 | 21 | 22 | 23 | 24 | 25 |
26 | 27 | 28 | 29 | 30 |